Find insight on Allianz, Zurich Insurance, Generali and more in the latest Market Talks covering Financial Services.

Eli Lilly (LLY) stock plunges as Phase 3 trial data for the company's oral weight loss drug orforglipron overshadow better ...

It's been a sad week for Organon & Co. ( NYSE:OGN ), who've watched their investment drop 13% to US$8.72 in the ...

Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs. Eli Lilly also released long-awaited ...